Beam Therapeutics Inc. is aiming to expand its gene therapy-development capabilities beyond products that target tissue in the liver with the acquisition of Guide Therapeutics, a firm focused on lipid nanoparticle (LNP) discovery.
Beam Looks Beyond Liver With Guide Therapeutics Acquisition
Company Pays $120m Upfront
Beam Therapeutics said acquiring Guide Therapeutics' IP could enable LNP delivery of gene-editing payloads to tissues other than the liver.
